Impact of Cilostazol versus Cilostazol and Selenium Combination on The Healing of Diabetic Foot Ulcer Patients: A Randomized Controlled Trial. [PDF]
Eliwa HE +3 more
europepmc +1 more source
Analysis of Treatment Pattern of Antiplatelet in First-Ever Ischemic Stroke Without Previous Antiplatelet Use: A Real-World Distributed Network Analysis of 11 Observational Korean Databases Using a Common Data Model. [PDF]
Park SH +18 more
europepmc +1 more source
Comparison of Efficacy and Safety of Cilostazol/Extract of Ginkgo biloba vs. Aspirin in Carotid Atherosclerosis in Patients with Diabetes Mellitus (Diabetes Metab J 2026;50:357-67). [PDF]
Hwang YC, Kim SY, Lim S.
europepmc +1 more source
Cilostazol increases collateral remodeling and reduces the severity of ischemic stroke. [PDF]
Zhang H, Ding MC, Gong G, Faber JE.
europepmc +1 more source
Cilostazol Contributes to Risk Reduction of Stroke Recurrence without Mediating a Reduction of Blood Pressure: Results from CSPS.com. [PDF]
Miwa K +12 more
europepmc +1 more source
Headache After Coil Embolization for Unruptured Intracranial Aneurysms (Non-Stent-Assisted Versus Stent-Assisted): A Prospective Comparative Cohort Study. [PDF]
Ban SP +11 more
europepmc +1 more source
Safety and effectiveness of clazosentan in patients after aneurysmal subarachnoid haemorrhage: a second interim report of a post-marketing surveillance in Japan. [PDF]
Sakata H +5 more
europepmc +1 more source
E<b>F</b>fects of Y-6 S<b>U</b>blingual Tablets for Pa<b>T</b>ients with Ac<b>U</b>te Ischemic St<b>R</b>ok<b>E</b> (FUTURE): a phase II, randomised, double-blind, double-dummy, placebo-controlled, parallel trial. [PDF]
Wang Y +14 more
europepmc +1 more source
Basilar Artery Dissection Diagnosed Using Fluid-Attenuated Inversion Recovery and Managed with Stepwise Antithrombotic Therapy: A Case Report. [PDF]
Dai M +6 more
europepmc +1 more source
Integrated computational screening of FDA-approved anticancer drugs as novel HPV-16 E6 inhibitors in cervical cancer. [PDF]
Ahmadi M, Yoosefian M.
europepmc +1 more source

